Nippon Life Global Investors Americas Inc. boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 67,800 shares of the medical instruments supplier’s stock after acquiring an additional 4,630 shares during the quarter. Nippon Life Global Investors Americas Inc.’s holdings in Becton, Dickinson and were worth $13,286,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Almanack Investment Partners LLC. purchased a new stake in shares of Becton, Dickinson and in the first quarter valued at approximately $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in shares of Becton, Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after buying an additional 240 shares in the last quarter. Parkside Financial Bank & Trust increased its position in shares of Becton, Dickinson and by 8.1% in the second quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock valued at $133,000 after buying an additional 51 shares in the last quarter. Harfst & Associates Inc. increased its position in shares of Becton, Dickinson and by 46.4% in the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after buying an additional 221 shares in the last quarter. Finally, Financial Architects Inc increased its position in shares of Becton, Dickinson and by 8.0% in the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after buying an additional 54 shares in the last quarter. Institutional investors own 88.46% of the company’s stock.

A number of analysts have recently commented on BDX shares. Piper Jaffray Companies restated a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Zacks Investment Research cut Becton, Dickinson and from a “hold” rating to a “sell” rating in a research report on Monday, October 9th. Royal Bank Of Canada restated a “hold” rating and issued a $210.00 price objective on shares of Becton, Dickinson and in a research report on Wednesday, October 25th. Morgan Stanley boosted their price objective on Becton, Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Finally, Stifel Nicolaus restated a “buy” rating and issued a $245.00 price objective on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $217.08.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at $226.33 on Monday. The company has a debt-to-equity ratio of 1.44, a current ratio of 5.58 and a quick ratio of 5.03. The stock has a market capitalization of $51,598.33, a P/E ratio of 23.85, a PEG ratio of 1.77 and a beta of 1.07. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $229.68.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.37 by $0.03. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The business’s revenue was down 2.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.12 earnings per share. research analysts predict that Becton, Dickinson and Company will post 10.65 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be paid a $0.75 dividend. The ex-dividend date is Thursday, December 7th. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.33%. Becton, Dickinson and’s payout ratio is currently 62.80%.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the transaction, the insider now owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Stephen Sichak sold 11,787 shares of the business’s stock in a transaction on Friday, September 8th. The stock was sold at an average price of $200.46, for a total value of $2,362,822.02. Following the transaction, the insider now directly owns 14,038 shares in the company, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/nippon-life-global-investors-americas-inc-buys-4630-shares-of-becton-dickinson-and-company-bdx/1742858.html.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.